Healthcare winners: HCA Holdings Inc (NYSE:HCA), Community Health Systems (NYSE:CYH), Universal Health Services (NYSE:UHS), Uniqure NV (NASDAQ:QURE)

Given the lack of management expertise and synergies, Wesfarmers could struggle to justify offering more for Healthscope than other mooted bidders, which include US healthcare company HCA Holdings Inc (NYSE:HCA), Chinese conglomerate Fosun Pharma and Malaysia’s IHH. HCA Holdings Inc (NYSE:HCA) stock performance was 5.76% in last session and finished the day at $53.44. Traded volume was 7.66million shares in the last session and the average volume of the stock remained 2.54million shares. The beta of the stock remained 1.69. HCA Holdings Inc (NYSE:HCA) insider ownership is 29.40%.

Shares of Community Health Systems (NYSE:CYH) have been given an average rating of “Buy” by the twenty-one brokerages that are covering the stock, Analyst Ratings Net reports. Six analysts have rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. Community Health Systems (NYSE:CYH) rose 6.60 percent to $39.92 Friday on volume of 2.69million shares. The intra-day range of the stock was $37.85 to $40.08. Community Health Systems (NYSE:CYH) has a market capitalization of $4.60billion.

Universal Health Services, Inc. (NYSE:UHS) announced today that its reported net income attributable to UHS was $138.1 million, or $1.38 per diluted share, during the first quarter of 2014 as compared to $119.8 million, or $1.21 per diluted share, during the comparable quarter of 2013. Universal Health Services, Inc. (NYSE:UHS)’s stock on Apr 25, 2014 reported a increase of 6.14% to the closing price of $82.92. Its fifty two weeks range is $63.51 -$86.08. The total market capitalization recorded $8.18billion. The overall volume in the last trading session was 1.71million shares. In its share capital, UHS has 98.75million outstanding shares.

The company behind Glybera, Uniqure NV (NASDAQ:QURE), has a series of other gene therapies undergoing clinical testing as well. Uniqure NV (NASDAQ:QURE)’s targets include diseases such as acute intermittent porphyria, Parkinson’s disease, and Sanfilippo syndrome. On Friday, shares of Uniqure NV (NASDAQ:QURE) advanced 8.37% to close the day at $11.00. Company monthly performance is recorded as -30.95%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone